Article Rich – Lifestyle
Author:
Cardiff Oncology, Inc.
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
April 27, 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
April 17, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
March 20, 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
March 19, 2026
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
March 5, 2026